SafeSciMET is a new and unique pan-European network, which will develop and establish a comprehensive modular education and training programme in safety sciences for medicines. The network brings together eighteen top institutes for drug safety education and research and fifteen pharmaceutical industry leaders. The SafeSciMET courses are open to all scientists from industry, academia and regulatory agencies and will encompass the safety, ethical, regulatory and societal aspects of drug discovery and development.
Professionals will be able to follow single courses in safety sciences or selected subsets of courses, to be accredited for Continuing Professional Development (CPD). Scientists successfully completing the full programme, including a Master thesis, will be awarded with an accredited Master of Advanced Safety Sciences of Medicines. All training courses will be aligned with the Bologna process.
The training will lead to a new generation of safety specialists with strong competences in the application of novel technologies in risk assessment. They will be able to perform reliable evaluations of the safety of drug candidates and new medicines by linking data from laboratory tests with patient data in a more effective way. More targeted training of scientists will speed up biopharmaceutical innovation and may lead to a cost reduction in drug development.
Early insight in the safety aspects of a candidate drug will reduce adverse effects in the later, clinical research phases and will improved the quality of life for patients, as a result of improved drug safety evaluation and regulatory procedures.
Achievements & News
BIOVISION and the IMI Education & Training projects
IMI and the IMI Education & Training projects participated in BIOVISION - the World Life Sciences Forum, which was held in Lyon, France, on March 24-26 2013. It is the place where key stakeholders ###debate the impact of the latest scientific advances on society and share their vision on how to overcome health, environment and nutrition challenges. IMI Executive Director Michel Goldman participated in the plenary session ‘How to make better use of collective intelligence’. Mike Hardman, project coordinator of EMTRAIN, represented IMI and the IMI E&T projects in the BIOVISION Investor Conference workshop. Moreover, the IMI E&T projects organised a satellite event on ‘Training and Education in Europe’ where they presented their activities to the forum’s participants at a booth in the exhibition area.
IMI Education & Training projects in the spotlight at DIA EuroMeeting 2013
This year’s DIA EuroMeeting, which was held in Amsterdam, the Netherlands from 4 to 6 March, featured an entire theme dedicated to IMI’s five Education & Training (E&T) projects. The sessions featured ###the latest news from the projects and demonstrated how they are helping to advance education in the biomedical sector in Europe. DIA EuroMeeting visitors could also catch up with the projects and find out how IMI’s E&T projects can boost their careers.
- View the agenda for the IMI theme in the DIA EuroMeeting programme (page 46)
Check out the IMI Education & Training projects’ video
Four of IMI’s Education & Training projects have put together a short video on their activities.###In the six-minute clip, the coordinators of the EMTRAIN, SafeSciMET, Eu2P, and PharmaTrain projects present their courses and the benefits they offer for students and course providers alike. The film also features a presentation by IMI Executive Director Michel Goldman.
SafeSciMET courses – sign up now!
SafeSciMET, the IMI Education & Training program for Safety Scientists, has successfully completed its first cycle of courses in 2012, with participants giving very positive feedback. ###The project has now announced the start of the second course cycle, which runs from 2012 to 2014. Registration is already open for a number of courses, including Drug safety of stem cells and other novel therapeutics (26-30 November, Liverpool, UK). Topics covered in this course include the basic biology of stem cells and molecular therapies, drug safety aspects of novel therapies, the regulatory requirements for stem cells and novel therapies, and the application of stem cells in the safety assessment of conventional compounds. A full list of forthcoming courses can be found online.
- Download an overview of the courses planned up until August 2014.
SafeSciMET launches courses on clinical safety
IMI Education and Training project SafeSciMET launches three new courses in the area of clinical safety. The course ‘Clinical safety:pre-approval’ runs on 21-25 May in Basel, Switzerland;### ‘Clinical safety: post-approval’ will run on 11-15 June in Lyon, France; and ‘Stratification, pharmacogenetics and drug safety’ runs on 27-31 August in Stockholm, Sweden. Applications for the new courses are now open via the project website.
SafeSciMET opens it's new 'safety programme
New safety programme on safety sciences' which includes courses on ‘safety pharmacology’; ‘non-clinical safety assessment: strategies, ethics and protocols’; ‘biomolecular analysis: from method development to clinic’; and ‘predictive cell culture'.
The IMI Education & Training project SafeSciMET has opened registrations to its first course, 'Drug Discovery and Development'
This is the introductory course to the new European Masters degree for Advanced Safety Sciences for Medicines designed by SafeSciMET. The course takes place in November 2010 and consists of 5 days at the University of Copenhagen with lectures, presentations and discussions, followed by one week home assignment of case studies and course questions.### Registration is open on the SafeSciMET website . A brochure on the course is available here . All the forthcoming SafeSciMET courses are listed on the website , any of them also available one by one, for instance for continuing professional development.
- F. Hoffmann-La Roche AG, Basel, Switzerland
- AstraZeneca AB, Södertälje, Sweden
- Laboratorios Almirall S.A., Barcelona, Spain
- Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
- Bayer Schering Pharma AG, Berlin, Germany
- Boehringer Ingelheim International GmbH, Ingelheim, Germany
- Eli Lilly and Company Limited, Basingstoke, United Kingdom
- Pfizer Limited, Sandwich, UK
- GlaxoSmithKline Research and Development LTD, Brentford, UK
- H. Lundbeck A/S, Valby, Denmark
- Merck KGAA, Darmstadt, Germany
- UCB Pharma SA, Brussels, Belgium
- Novartis Pharma AG, Basel, Switzerland
- Novo Nordisk A/S, Bagsvaerd, Denmark
- Orion Corporation, Espoo, Finland
Universities, Research Organisations, Public Bodies & Non-profit
- VU University, Amsterdam, The Netherlands
- Universitat Konstanz, Konstanz, Germany
- University of Surrey, Guildford, United Kingdom
- Uppsala Universitet, Uppsala, Sweden
- European Federation for Pharmaceutical Sciences, Stockholm, Sweden
- Københavns Universitet, København K, Denmark
- Universiteit Leiden, Leiden, Netherlands
- Top Institute Pharma, Leiden, Netherlands
- Universität Basel, Basel, Switzerland
- Universite Henri Poincare Nancy 1, Nancy, France
- Hospices Civils de Lyon, Lyon, France
- Martin-Luther-Universität Halle-Wittenberg, Halle, Germany
- Karolinska Institutet, Stockholm, Sweden
- Universität Wien, Wien, Austria
- Université Paris-Sud XI, Orsay, France
- The University of Liverpool, Liverpool, United Kingdom
- Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
- Charite - Universitätsmedizin Berlin, Berlin, Germany
Facts & Figures
|IMI funding||2 216 405|
|EFPIA in-kind||786 041|
|Other||3 391 459|
|Total cost||6 393 905|
Global Non-clinical Drug Safety,
F. Hoffmann-La Roche,
Email: christian.freichel [AT] roche.com
Managing entity of IMI beneficiaries
Nico P.E. Vermeulen
LACDR, Department of Chemistry and Pharmaceutical Sciences,
Tel: +31 (0)20 598 7590
Email: npe.vermeulen [AT] few.vu.nl